Disc Medicine, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Disc Medicine, Inc. (IRON) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-02-27
- Disc Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- Disc Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- Disc Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- Disc Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- Disc Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Disc Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.11M.
- Disc Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Disc Medicine, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $1.67M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $1.11M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.11M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $1.11M 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $0.00 10-K · filed 2024-03-21 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-11 | |||
| 2021-12-31 | $1.67M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |